YOLFTbeta
ViroGates A/S

ViroGates A/S

VIRO · CO · Healthcare / Medical Devices

7.10DKK-0.50 (-6.58%)

Price History

Full chart

Market Stats

Previous Close7.60
Open7.05
Day Range6.80 – 7.40
52-Week Range7.60 – 17.40
Volume3.48K
Market Cap78.90M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.88
Dividend Yield0.00%
Beta0.61
50-Day Avg10.31
200-Day Avg10.98

About

ViroGates A/S, an in vitro diagnostics company, develops and sells blood tests for measuring chronic inflammation for the healthcare sector. It offers suPARnostic TurbiLatex, a CE-IVD approved particle-enhanced turbidimetric immunoassay for quantitative measurement of suPAR in human plasma; suPARnostic AUTO Flex ELISA kit, a fully quantitative immunoassay designed for accurate and reliable measurement of soluble urokinase plasminogen activator receptor in human plasma; and suPARnostic Quick Triage, a test for rapid, quantitative measurement of suPAR levels. ViroGates A/S was founded in 2000 and is headquartered in Birkerød, Denmark.

Company Details

  • SectorHealthcare
  • IndustryMedical Devices
  • CEOMr. Jakob Ole Knudsen
  • Employees7
  • HeadquartersBanevaenget 13, Birkerød, Denmark, 3460, Denmark
  • Websitehttps://www.virogates.com

Leadership

  • Mr. Jakob Ole KnudsenChief Executive Officer · b. 1968
  • Dr. Jesper Eugen-OlsenCo-Founder & Chief Scientific Officer · b. 1963
  • Ms. Josephine Baum JorgensenChief Financial Officer · b. 1991
  • Ms. May Britt DyvelkovVice President of Accounting · b. 1960
  • Dr. Thomas KrarupVice President of Global Sales & Marketing · b. 1963

Financials

Income Statement

Currency: DKK2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue3.59M3.69M2.44M3.32M3.58M5.35M7.66M15.20M6.99M4.90M5.31M
Growth (%)-+2.59%-33.78%+35.85%+8.02%+49.47%+43.00%+98.50%-54.02%-29.91%+8.37%
Cost of Revenue5.29M356.00K271.00K312.00K384.00K1.16M1.87M2.54M1.18M2.33M2.28M
Gross Profit-1.69M3.33M2.17M3.00M3.20M4.19M5.79M12.66M5.80M2.56M3.02M
Gross Margin-47.15%90.34%88.90%90.59%89.28%78.26%75.60%83.28%83.08%52.36%56.98%
Operating Expense3.66M10.27M9.86M21.11M22.92M23.92M24.58M23.50M18.37M19.37M17.09M
Operating Income-5.36M-6.94M-7.69M-18.10M-19.72M-19.73M-18.79M-10.85M-12.56M-16.80M-14.07M
Operating Margin-149.07%-188.20%-315.12%-545.90%-550.61%-368.49%-245.42%-71.36%-179.83%-343.17%-265.10%
EBITDA-5.26M-6.84M-7.57M-17.97M-19.59M-19.50M-18.57M-10.59M-12.48M-14.52M-14.07M
EBITDA Margin-146.28%-185.51%-310.16%-541.86%-547.04%-364.21%-242.58%-69.68%-178.63%-296.55%-265.10%
Net Income-4.07M-5.40M-5.99M-16.99M-18.80M-18.74M-17.66M-9.65M-12.10M-14.35M-10.40M
Net Income Margin-113.28%-146.58%-245.27%-512.24%-524.76%-349.94%-230.71%-63.47%-173.12%-292.93%-195.91%
R&D--4.27M4.28M5.58M5.80M5.94M10.58M6.44M6.91M8.14M
R&D as % of Total Revenue--175.09%129.01%155.89%108.29%77.55%69.62%92.21%141.07%153.44%
Interest Expense039.00K7.00K823.00K298.00K287.00K194.00K112.00K569.00K658.00K803.00K
Interest Expense % of Total Revenue0.00%1.06%0.29%24.82%8.32%5.36%2.53%0.74%8.14%13.44%15.13%

Balance Sheet

Currency: DKK2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets17.41M12.00M4.98M63.42M45.16M38.25M20.23M17.54M24.55M17.66M30.59M
Total Liabilities3.03M3.01M1.98M2.41M2.94M6.93M3.80M1.45M7.55M6.87M11.19M
Total Equity14.39M8.98M3.00M61.01M42.22M31.31M16.43M16.09M17.01M10.79M19.40M
Cash14.50M7.82M1.47M60.08M41.41M33.53M14.86M9.88M16.03M12.21M26.30M
Total Debt--------5.30M5.30M4.62M
Net Debt-14.50M-7.82M-1.47M-60.08M-41.41M-33.53M-14.86M-9.88M-10.73M-6.91M-21.67M

Cash Flow

Currency: DKK2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-6.68M-6.68M-6.22M-16.38M-18.07M-15.60M-21.44M-14.28M-12.18M-11.95M-4.13M
Investing Cash Flow-2.00K-2.00K-132.00K-2.00K-603.00K-114.00K-4.00K-13.00K12.00K-4.00K5.00K
Financing Cash Flow75.00M75.00M75.00M75.00M7.83M7.83M2.78M9.31M18.32M8.13M18.21M
Capital Expenditure130.00K130.00K130.00K546.00K546.00K114.00K00000
Free Cash Flow--6.68M-6.35M-16.38M-18.62M-15.72M-21.44M-14.28M-12.18M-11.95M-4.13M
FCF to OCF-100.00%102.09%100.00%103.02%100.73%100.00%100.00%100.00%100.00%100.00%

Earnings

Report DateJun 30, 2018Sep 30, 2018Dec 31, 2018Mar 31, 2019Jun 30, 2019Nov 27, 2019Mar 25, 2020May 4, 2020Jul 28, 2020Oct 27, 2020Mar 25, 2021Apr 29, 2021Aug 19, 2021Nov 11, 2021Mar 23, 2022May 4, 2022Aug 18, 2022Nov 10, 2022Mar 29, 2023May 4, 2023Aug 17, 2023Nov 9, 2023Mar 21, 2024May 2, 2024Aug 15, 2024Nov 7, 2024Mar 24, 2025Apr 24, 2025Aug 21, 2025Nov 7, 2025Mar 26, 2026May 8, 2026Aug 21, 2026
EPS Estimate---------------------------------
EPS Actual-2.07-0.56-0.92-0.93-1.11-1.02-1.72-1.57-1.10-0.93-1.42-1.37-1.25-1.07-0.98-0.72-0.47-0.68-0.41-0.68-0.85-0.49-0.51-0.56-0.64-0.35-0.57-0.36-0.42-0.25-0.29-0.28-0.06
Surprise---------------------------------
Timing---------------------------------

Key Statistics & Ratios

Market Cap78.90M
Enterprise Value79.12M
Trailing P/E0.00
Forward P/E0.00
Price / Sales8.43
Price / Book5.73
EPS-0.88
Book Value1.75
Revenue (TTM)9.36M
Gross Profit (TTM)7.32M
EBITDA-14.52M
Profit Margin-80.81%
Operating Margin-26.65%
Return on Equity-72.15%
Return on Assets-26.66%
Shares Outstanding9.28M
Shares Float2.37M
Beta0.61
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Nov 28, 202383:64